# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Castleman's Disease

Angiofollicular ganglionic hyperplasia
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-9 of 9 results.
BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)
Status: Recruiting
Last Changed: Jun 12, 2019
First Received: Jun 12, 2019
Disease(s): Idiopathic Multicentric Castleman's Disease
Intervention(s): Bortezomib, Cyclophosphamide, Dexamethason
Locations: Peking Union Medical College Hospital, Beijing, Beijing, China
TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial
Status: Recruiting
Last Changed: Feb 06, 2017
First Received: Feb 03, 2017
Disease(s): Multicentric Castleman Disease
Intervention(s): Thalidomide, cyclophosphamide and prednisone
Locations: Peking Union Medical College Hospital, Beijing, Beijing, China
International Registry for Patients With Castleman Disease
Status: Recruiting
Last Changed: Aug 28, 2019
First Received: Jun 29, 2016
Disease(s): Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node, Lymph Node Hyperplasia, Giant
Locations: University of Pennsylvania, Philadelphia, Pennsylvania, United States
Hopital Cl Huriez, Lille, Nord, France
Hopital Saint-Louis, Paris, France
Universitätsklinikum Münster, Munster, NRW, Germany
Infektionsmedizinisches Centrum, Hamburg, Germany
... and 6 other locations.
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
Status: Recruiting
Last Changed: Jan 18, 2020
First Received: Oct 04, 2017
Disease(s): Human Immunodeficiency Virus, Castleman's Disease, Kaposi's Sarcoma, Viral-Associated Cancer
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
Status: Recruiting
Last Changed: Feb 17, 2020
First Received: Sep 22, 2004
Disease(s): Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
Intervention(s): Etoposide, Interferon-alpha, Rituximab, Zidovudine, Liposomal Doxorubicin, Bortezomib, Valganciclovir, Doxorubicin, Vincristine, Cyclophosphamide, Filgrastim (G-CSF), Prednisone, Sirolimus, Observation Only
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Status: Recruiting
Last Changed: Apr 02, 2020
First Received: Nov 23, 2000
Disease(s): HIV, Kaposi's Sarcoma, Lymphomas, Multicentric Castleman's Disease, Primary Effusion Lymphoma
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Registry for Adults With Plasma Cell Disorders (PCD's)
Status: Recruiting
Last Changed: Oct 24, 2018
First Received: Oct 24, 2018
Disease(s): Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease, Light Chain Deposition Disease, Heavy Chain Deposition Disease, Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes, Smoldering Multiple Myeloma, Plasma Cell Leukemia
Locations: North Carolina Cancer Hospital, Chapel Hill, North Carolina, United States
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
Status: Recruiting
Last Changed: Sep 17, 2019
First Received: Mar 13, 2012
Disease(s): Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
Intervention(s): Bevacizumab, Cetuximab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, Valproic Acid
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
Status: Recruiting
Last Changed: Apr 03, 2020
First Received: Jan 21, 2016
Disease(s): Kaposi Sarcoma
Intervention(s): liposomal doxorubicin, pomalidomide
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States